Novogene AMEA
  • Novogene AMEA
  • Genomics
    • Human Whole Genome Sequencing
    • Plant and Animal Whole Genome Sequencing
    • Microbial Whole Genome Sequencing
    • Plant and Animal De novo Sequencing
    • Microbial De novo Sequencing
    • Shotgun Metagenomics Sequencing
    • Amplicon Sequencing
    • Whole Exome Sequencing
    Transcriptomics
    • mRNA Sequencing
    • Total RNA Sequencing
    • Full-Length Transcriptome Sequencing
    • Whole Transcriptome Sequencing
    • Small RNA Sequencing
    • Circular RNA Sequencing
    • Metatranscriptome Sequencing
    • Prokaryotic RNA Sequencing
    Single Cell & Spatial Omics
    • Single Cell Gene Expression
    • Single Cell Immune Profiling Sequencing
    • Single Cell Long Read Transcriptome
    • Visium HD Spatial Gene Expression
    • Stereo-Seq Spatial Gene Expression
    • Xenium In Situ Spatial Transcriptome
    Epigenomics
    • Whole Genome Bisulfite Sequencing (WGBS)
    • Directed DNA Methylation Sequencing (DM-Seq) NEW
    • Reduced Representation Bisulfite Sequencing (RRBS)
    • Chromatin Immunoprecipitation Sequencing (ChIP-seq)
    • RNA Immunoprecipitation Sequencing (RIP-seq)
    • Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-seq)

    Premade Library

    • Sequencing Only on Illumina Sequencer
    • Sequencing Only on PacBio Sequencer
    Proteomics and Metabolomics
    • Olink Proteomics
    • Quantitative Proteomics
    • Untargeted Metabolomics
  • PromotionsPromotions
    • Platforms
    • Automated Delivery Platform (Falcon)
    • Bioinformatics Analysis Tool (NovoMagic)
    • Customer Service System (CSS)
    • Brochures
    • Case Studies
    • Webinar
    • Blog
    • Sample Guidelines
    • Cancer Research
    • Immuno-oncology
    • Agrigenomics
    • Environment
    • Food Science
    • Human Microbiome
    • Plant and Animal Microbiome
    • Drug Discovery and Development
    • Rare and Complex Diseases
    • About Us
    • Our Locations
    • News
    • Careers
  • Contact UsContact Us
  1. Home
  2. Resources
  3. Therapy-induced APOBEC3A Drives Evolution of Persistent Cancer Cells

Therapy-induced APOBEC3A Drives Evolution of Persistent Cancer Cells

Introduction:

Published on August 23, 2023, in the prestigious journal Nature, a study led by Dr Kazuo Isozaki, alongside teams from renowned oncology research centers, explored the intriguing evolution of resistance mutations in non-small cell lung cancers (NSCLCs) treated with tyrosine kinase inhibitors (TKIs). The research in this paper focused on the following key questions:

  • How do non-small cell lung cancers (NSCLCs) develop resistance to tyrosine kinase inhibitors (TKIs)?
  • What role does APOBEC3A-induced mutagenesis play in the evolution of drug-resistant cancer cells?
  • Are there specific mutational signatures associated with APOBEC activity in TKI-treated tumors?
  • Can inhibiting APOBEC3A expression or activity prevent or delay the emergence of drug resistance in NSCLC?

ServicesServices menu

SupportSupport menu

CompanyCompany menu

Services
Whole Genome SequencingDe novo SequencingAmplicon SequencingShotgun Metagenomic SequencingDirected DNA Methylation Sequencing (DM-Seq)mRNA SequencingSingle Cell Gene ExpressionVisium HD Spatial Gene ExpressionXenium In Situ Spatial TranscriptomeOlink ProteomicsUntargeted Metabolomics
Support
NovoMagic Bioinformatics Analysis ToolCustomer Service SystemFalcon Intelligent Delivery Platform
Company
About UsOur LocationsOur PlatformsNewsCareersContact Us
LinkedInLinkedIn hoverYouTubeYouTube hoverXX hover
Copyright © 2026 Novogene Inc. All rights reserved.For Research Use Only. Not for Clinical Diagnostic Use.
Novogene AMEA
  • Novogene AMEA
  • Genomics
    • Human Whole Genome Sequencing
    • Plant and Animal Whole Genome Sequencing
    • Microbial Whole Genome Sequencing
    • Plant and Animal De novo Sequencing
    • Microbial De novo Sequencing
    • Shotgun Metagenomics Sequencing
    • Amplicon Sequencing
    • Whole Exome Sequencing
    Transcriptomics
    • mRNA Sequencing
    • Total RNA Sequencing
    • Full-Length Transcriptome Sequencing
    • Whole Transcriptome Sequencing
    • Small RNA Sequencing
    • Circular RNA Sequencing
    • Metatranscriptome Sequencing
    • Prokaryotic RNA Sequencing
    Single Cell & Spatial Omics
    • Single Cell Gene Expression
    • Single Cell Immune Profiling Sequencing
    • Single Cell Long Read Transcriptome
    • Visium HD Spatial Gene Expression
    • Stereo-Seq Spatial Gene Expression
    • Xenium In Situ Spatial Transcriptome
    Epigenomics
    • Whole Genome Bisulfite Sequencing (WGBS)
    • Directed DNA Methylation Sequencing (DM-Seq) NEW
    • Reduced Representation Bisulfite Sequencing (RRBS)
    • Chromatin Immunoprecipitation Sequencing (ChIP-seq)
    • RNA Immunoprecipitation Sequencing (RIP-seq)
    • Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-seq)

    Premade Library

    • Sequencing Only on Illumina Sequencer
    • Sequencing Only on PacBio Sequencer
    Proteomics and Metabolomics
    • Olink Proteomics
    • Quantitative Proteomics
    • Untargeted Metabolomics
  • PromotionsPromotions
    • Platforms
    • Automated Delivery Platform (Falcon)
    • Bioinformatics Analysis Tool (NovoMagic)
    • Customer Service System (CSS)
    • Brochures
    • Case Studies
    • Webinar
    • Blog
    • Sample Guidelines
    • Cancer Research
    • Immuno-oncology
    • Agrigenomics
    • Environment
    • Food Science
    • Human Microbiome
    • Plant and Animal Microbiome
    • Drug Discovery and Development
    • Rare and Complex Diseases
    • About Us
    • Our Locations
    • News
    • Careers
  • Contact UsContact Us
  1. Home
  2. Resources
  3. Therapy-induced APOBEC3A Drives Evolution of Persistent Cancer Cells

Therapy-induced APOBEC3A Drives Evolution of Persistent Cancer Cells

Introduction:

Published on August 23, 2023, in the prestigious journal Nature, a study led by Dr Kazuo Isozaki, alongside teams from renowned oncology research centers, explored the intriguing evolution of resistance mutations in non-small cell lung cancers (NSCLCs) treated with tyrosine kinase inhibitors (TKIs). The research in this paper focused on the following key questions:

  • How do non-small cell lung cancers (NSCLCs) develop resistance to tyrosine kinase inhibitors (TKIs)?
  • What role does APOBEC3A-induced mutagenesis play in the evolution of drug-resistant cancer cells?
  • Are there specific mutational signatures associated with APOBEC activity in TKI-treated tumors?
  • Can inhibiting APOBEC3A expression or activity prevent or delay the emergence of drug resistance in NSCLC?

ServicesServices menu

SupportSupport menu

CompanyCompany menu

Services
Whole Genome SequencingDe novo SequencingAmplicon SequencingShotgun Metagenomic SequencingDirected DNA Methylation Sequencing (DM-Seq)mRNA SequencingSingle Cell Gene ExpressionVisium HD Spatial Gene ExpressionXenium In Situ Spatial TranscriptomeOlink ProteomicsUntargeted Metabolomics
Support
NovoMagic Bioinformatics Analysis ToolCustomer Service SystemFalcon Intelligent Delivery Platform
Company
About UsOur LocationsOur PlatformsNewsCareersContact Us
LinkedInLinkedIn hoverYouTubeYouTube hoverXX hover
Copyright © 2026 Novogene Inc. All rights reserved.For Research Use Only. Not for Clinical Diagnostic Use.
Privacy PolicyCookie PolicyCareers
Privacy PolicyCookie PolicyCareers